| Literature DB >> 11550026 |
N E Kushlinskii1, T A Britvin, S G Abbasova, A G Perevoshchikov, V V Prorokov, I A Kostanyan, V I Knysh, V M Lipkin.
Abstract
Serum concentration of soluble Fas antigen (sFas) was measured in 60 normal subjects and 33 patients with colon cancer. The incidence of sFas detection and its serum content were higher in patients with colon cancer compared to normal subjects. No relationships between the incidence and level of sFas and patient's sex, age, duration and stage of the disease were found. Serum content of sFas tended to increase in patients with metastases to regional lymph nodes, liver, and lungs. The role of sFas as a marker predicting clinical course and outcome of colon cancer is discussed.Entities:
Mesh：
Substances：
Year: 2001 PMID： 11550026 DOI： 10.1023/a:1017908320634
Source DB: PubMed Journal: Bull Exp Biol Med ISSN： 0007-4888 Impact factor: 0.804